Winners and Losers in Big Pharma
692929
Some drugmakers are hitting a slump, but not all of them. Which ones can still cure what ails your portfolio?
178334
The Motley Fool - Pharmaceutical investors often forget that places beyond the United States and European Union have their own regulatory bodies that approve drugs -- and that some of these markets can be quite lucrative. Canada, Japan, and Australia are home to some of the biggest economies in the world, and they all have their own independent drug-regulation entities.
468846
A few years ago, drug giant Bristol-Myers Squibb Co. announced it was retooling its strategy, meaning a drug it was developing for insomnia was probably headed for the sidelines. Vanda Pharmaceuticals Inc. pounced.
492704
Intensive marketing has helped create blockbuster drugs that aren't necessarily more effective than cheaper alternatives.
479126
Strong drug sales provide a dose of good medicine for this pharmaceutical company.
372947
Stocks of branded and generic drug makers closed down a bit Tuesday as clinical study results mixed with merger updates. One of the big winners on the day was Nektar Therapeutics, on news that Exubera, the
9936
Big pharmaceutical companies sometimes calculated to the penny the profits that doctors could make from their cancer drugs and shared those estimates with doctors.
264861
Osteoporosis drug could give the company its next big winner.
184248
Averse to risk? Check out these nontraditional drug companies.
683001
Patients taking an experimental multiple sclerosis drug developed by Biogen Idec Inc.  and Elan Corp.  experienced far fewer relapses in a clinical trial, data that analysts say could give the drug a dominant market position.
37904
The drug maker's difficulties are evident, but its productivity may make it worth a second look.
714241
Synta Pharmaceuticals Corp. knows a thing or two about developing drugs. It has pretty impressive skills when it comes to money, too.
547519
Generic drug wars and speculation on who will head Merck &amp; Co. next started to turn drug makers&#39; stocks around after the sector&#39;s benchmark index fell 4 percent and hit a 52-week low last week.
101669
A new analysis finds that clinical trials of breast-cancer treatments by drugmakers show positive results far more often than non-industry trials. Why the difference?
520589
Investors are discouraged after it releases the latest data for its top drug.
435276
The troubled pharmaceutical company begins to show signs of life.
640850
SHANGHAI -- Looking at the facts, the past year seems to have been disastrous for Worldbest Pharmaceutical.  First, there were reports of accounting irregularities and exaggerated profit. Half the managers were fired. Then, in the summer, six people died and at least 80 fell ill after receiving an...